Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
[PubMed - indexed for MEDLINE]
2.

Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications.

Greenlee JE.

Int MS J. 2006 Nov;13(3):100-7. Review.

PMID:
17101078
[PubMed - indexed for MEDLINE]
3.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
[PubMed - indexed for MEDLINE]
4.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
[PubMed - indexed for MEDLINE]
5.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.

Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105. Review.

PMID:
22312009
[PubMed - indexed for MEDLINE]
6.

Progressive multifocal leukoencephalopathy.

Weissert R.

J Neuroimmunol. 2011 Feb;231(1-2):73-7. doi: 10.1016/j.jneuroim.2010.09.021. Review.

PMID:
20937530
[PubMed - indexed for MEDLINE]
7.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
[PubMed - indexed for MEDLINE]
8.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
[PubMed - indexed for MEDLINE]
9.

Advances in the management of PML: focus on natalizumab.

Fox R.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S33-7. doi: 10.3949/ccjm.78.s2.08. Review. Erratum in: Cleve Clin J Med. 2012 May;79(5):312.

PMID:
22123933
[PubMed - indexed for MEDLINE]
Free Article
10.

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME.

J Autoimmun. 2008 Feb-Mar;30(1-2):90-8. doi: 10.1016/j.jaut.2007.11.013. Review.

PMID:
18191544
[PubMed - indexed for MEDLINE]
11.

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Hunt D, Giovannoni G.

Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092. Review.

PMID:
22258169
[PubMed - indexed for MEDLINE]
12.

Natalizumab.

Berger JR.

Drugs Today (Barc). 2006 Oct;42(10):639-55. Review.

PMID:
17136224
[PubMed - indexed for MEDLINE]
13.

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB.

Lancet Neurol. 2007 May;6(5):431-41. Review.

PMID:
17434098
[PubMed - indexed for MEDLINE]
14.

The human JC polyomavirus (JCPyV): virological background and clinical implications.

Hirsch HH, Kardas P, Kranz D, Leboeuf C.

APMIS. 2013 Aug;121(8):685-727. doi: 10.1111/apm.12128. Epub 2013 Jun 19. Review.

PMID:
23781977
[PubMed - indexed for MEDLINE]
15.

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL.

Lancet Oncol. 2009 Aug;10(8):816-24. doi: 10.1016/S1470-2045(09)70161-5. Review.

PMID:
19647202
[PubMed - indexed for MEDLINE]
16.

Reactivation of JC virus and development of PML in patients with multiple sclerosis.

Khalili K, White MK, Lublin F, Ferrante P, Berger JR.

Neurology. 2007 Mar 27;68(13):985-90. Review.

PMID:
17389301
[PubMed - indexed for MEDLINE]
17.

"Thinking without thinking" about natalizumab and PML.

Ransohoff RM.

J Neurol Sci. 2007 Aug 15;259(1-2):50-2. Epub 2007 May 22. Review.

PMID:
17521672
[PubMed - indexed for MEDLINE]
18.

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L.

Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. Review.

PMID:
16635435
[PubMed - indexed for MEDLINE]
19.

Progressive multifocal leukoencephalopathy and newer biological agents.

Berger JR.

Drug Saf. 2010 Nov 1;33(11):969-83. doi: 10.2165/11537510-000000000-00000. Review.

PMID:
20925435
[PubMed - indexed for MEDLINE]
20.

The link between VLA-4 and JC virus reactivation.

Monaco MC, Major EO.

Expert Rev Clin Immunol. 2012 Jan;8(1):63-72. doi: 10.1586/eci.11.85. Review.

PMID:
22149341
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk